Researchers are rethinking how we target bowel cancer growth pathways, using patient-derived organoids to identify whether ...

A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...

Cancer stem cells (CSCs), a critical subpopulation within tumors, drive cancer initiation, progression, metastasis, relapse, ...

Daraxonrasib improved survival in metastatic pancreatic cancer in Phase III, signaling meaningful progress for therapies targeting RAS‑driven disease.

A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy ...

Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies at the American Association for Cancer Research (AACR) Annual Meeting 2026.

Co-primary efficacy in RAS G12–mutant PDAC included statistically significant OS and PFS gains assessed by blinded ...

Researchers at Ben-Gurion University of the Negev have identified a protein that plays a central role in enabling aggressive ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

This important paper substantially advances our understanding of how Molidustat may work, beyond its canonical role, by identifying its therapeutic targets in cancer. This study presents a compelling ...

Recently, a significant study conducted collaboratively by multiple hospitals in Shanghai was published in the prestigious ...